Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

@article{Perez2013ImpactOP,
  title={Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.},
  author={Edith A. Perez and Amylou C Dueck and Ann E. McCullough and Beiyun Chen and Xochiquetzal J. Geiger and R. Brian Jenkins and Wilma L. Lingle and Nancy E. Davidson and Silvana Martino and Peter A. Kaufman and Leila A. Kutteh and George W. Sledge and Lyndsay N. Harris and Julie R. Gralow and Monica M. Reinholz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 17},
  pages={2115-22}
}
PURPOSE It has been suggested that PTEN, a negative regulator of PI3K/AKT signaling, is involved in tumor sensitivity to trastuzumab. We investigated the association between tumor PTEN protein expression and disease-free survival (DFS) of patients randomly assigned to receive chemotherapy alone (arm A) or chemotherapy with sequential (arm B) or concurrent trastuzumab (arm C) in the phase III early-stage human epidermal growth factor receptor 2 (HER2) -positive trial-North Central Cancer… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial

  • S Loi, S Michiels, D Lambrechts
  • J Clin Oncol 30:8s,
  • 2012

Similar Papers

Loading similar papers…